Jefferies lowers Medtronic stock price target on valuation By Investing.com

Medtronic reported Q4 fiscal 2026 revenue of $9.8 billion, topping the $9.62 billion consensus, with 6.6% organic growth and EPS of $1.55 roughly in line with estimates. Fiscal 2027 revenue guidance of 6.75% to 7.25% also points to continued growth, though Jefferies cut its price target to $88 from $95 while keeping a Hold rating. The stock remains near its 52-week low at $77.95 and continues to offer a 3.64% dividend yield after 50 consecutive years of dividend payments.

Analysis

MDT is less a clean fundamentals story than a debate about whether the market is underpricing the durability of its non-core growth engine. The important second-order effect is that accelerating surgical robotics and procedure-adjacent categories can reshape hospital purchasing behavior: once a system is embedded, follow-on consumables, service, and training revenue tend to raise switching costs and smooth the revenue curve over multiple budget cycles.

The mixed guide matters because it creates a near-term valuation gap between headline growth and EPS quality. If management is effectively funding growth with margin pressure and launch costs, the stock may stay range-bound until investors get proof that the new product cycle converts into operating leverage rather than just higher top-line volatility. That makes the next 1-2 quarters more important than the annual guide: the key question is whether procedure growth and utilization can offset pricing and mix headwinds before sentiment cools.

For competitors, the issue is not just share loss but capex reprioritization. If MDT sustains mid-to-high single digit growth in adjacent categories, smaller medtech names with less scale may be forced into heavier discounting or M&A to defend channel access, while large peers with slower innovation cycles risk multiple compression. The dividend support also creates a quasi-floor, but that floor is only useful if cash conversion stays intact; any sign that growth is consuming free cash flow could quickly weaken the support thesis.

The contrarian read is that the market may be extrapolating too much from a few strong quarters in a still-fragile category mix. The stock can look cheap on sales, but if the new product ramp takes longer to monetize, the earnings base may remain structurally lower than bulls expect. In that case, the better trade is not a blind long, but a relative-value expression versus other large-cap medtech names with cleaner margin expansion.

Key Decisions for Investors

• Long MDT / short a slower-growth large-cap medtech peer basket for 3-6 months: own the company with the clearest category acceleration while hedging sector beta; target 8-12% relative upside if execution stays strong.
• Buy MDT call spreads 3-6 months out on pullbacks toward the low $70s: upside is tied to confirmation that growth converts into operating leverage, with defined downside if margin skepticism persists.
• If MDT rallies on the next print but guidance remains conservative, take profits into strength and rotate into lower-multiple peers with better EPS revision momentum; this stock likely needs a clean margin inflection to rerate materially.
• For event risk, watch the next two quarterly updates rather than the annual guide; if organic growth holds while EPS inflects even modestly, add to longs, but if margins miss again, expect the range to break lower.